Chromocell Therapeutics (CHRO) Competitors $1.84 +0.59 (+46.61%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.88 +0.04 (+2.45%) As of 04/17/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CHRO vs. SRZN, ESLA, KZR, SCYX, COEP, OSTX, ALGS, NRXP, MRNS, and LTRNShould you be buying Chromocell Therapeutics stock or one of its competitors? The main competitors of Chromocell Therapeutics include Surrozen (SRZN), Estrella Immunopharma (ESLA), Kezar Life Sciences (KZR), SCYNEXIS (SCYX), Coeptis Therapeutics (COEP), OS Therapies (OSTX), Aligos Therapeutics (ALGS), NRx Pharmaceuticals (NRXP), Marinus Pharmaceuticals (MRNS), and Lantern Pharma (LTRN). These companies are all part of the "pharmaceutical products" industry. Chromocell Therapeutics vs. Surrozen Estrella Immunopharma Kezar Life Sciences SCYNEXIS Coeptis Therapeutics OS Therapies Aligos Therapeutics NRx Pharmaceuticals Marinus Pharmaceuticals Lantern Pharma Surrozen (NASDAQ:SRZN) and Chromocell Therapeutics (NYSE:CHRO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, earnings and profitability. Do institutionals and insiders believe in SRZN or CHRO? 66.6% of Surrozen shares are owned by institutional investors. Comparatively, 78.0% of Chromocell Therapeutics shares are owned by institutional investors. 43.5% of Surrozen shares are owned by company insiders. Comparatively, 16.4% of Chromocell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has preferable earnings & valuation, SRZN or CHRO? Chromocell Therapeutics has lower revenue, but higher earnings than Surrozen. Chromocell Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSurrozen$10.66M3.00-$43.04M-$21.77-0.45Chromocell TherapeuticsN/AN/A-$7.38M-$1.47-1.25 Does the MarketBeat Community believe in SRZN or CHRO? Surrozen received 5 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Chromocell Therapeutics an outperform vote while only 28.57% of users gave Surrozen an outperform vote. CompanyUnderperformOutperformSurrozenOutperform Votes628.57% Underperform Votes1571.43% Chromocell TherapeuticsOutperform Votes1100.00% Underperform VotesNo Votes Do analysts prefer SRZN or CHRO? Surrozen currently has a consensus target price of $38.50, suggesting a potential upside of 294.87%. Given Surrozen's higher probable upside, research analysts clearly believe Surrozen is more favorable than Chromocell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Surrozen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Chromocell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SRZN or CHRO more profitable? Chromocell Therapeutics' return on equity of 0.00% beat Surrozen's return on equity.Company Net Margins Return on Equity Return on Assets SurrozenN/A -120.51% -54.68% Chromocell Therapeutics N/A N/A -453.90% Which has more volatility & risk, SRZN or CHRO? Surrozen has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Chromocell Therapeutics has a beta of 4.41, meaning that its stock price is 341% more volatile than the S&P 500. Does the media favor SRZN or CHRO? In the previous week, Surrozen and Surrozen both had 1 articles in the media. Surrozen's average media sentiment score of 1.00 beat Chromocell Therapeutics' score of 0.00 indicating that Surrozen is being referred to more favorably in the media. Company Overall Sentiment Surrozen Positive Chromocell Therapeutics Neutral SummarySurrozen beats Chromocell Therapeutics on 8 of the 14 factors compared between the two stocks. Get Chromocell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRO vs. The Competition Export to ExcelMetricChromocell TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$11.23M$2.84B$5.31B$18.42BDividend YieldN/A1.86%5.47%4.18%P/E Ratio-1.2530.4821.9431.09Price / SalesN/A441.91380.9426.53Price / CashN/A168.6838.3117.52Price / Book-1.123.466.454.30Net Income-$7.38M-$72.06M$3.22B$1.02B7 Day Performance42.08%2.57%5.85%1.42%1 Month Performance25.17%-15.93%-9.58%-7.92%1 Year Performance19.48%-25.72%11.85%1.71% Chromocell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHROChromocell TherapeuticsN/A$1.84+46.6%N/A+19.5%$11.23MN/A-1.254News CoverageGap UpHigh Trading VolumeSRZNSurrozen3.5953 of 5 stars$9.80-10.8%$38.50+292.9%+3.7%$31.85M$10.66M-0.4580Short Interest ↓Gap UpESLAEstrella Immunopharma2.9131 of 5 stars$0.85-3.4%$16.00+1,782.4%-25.8%$31.83MN/A-3.27N/AShort Interest ↓Positive NewsKZRKezar Life Sciences3.7406 of 5 stars$4.35+5.6%$39.50+808.0%-47.3%$31.78M$7M-0.3360Positive NewsSCYXSCYNEXIS0.1939 of 5 stars$0.81-3.7%N/A-37.2%$31.52M$3.75M-1.0960Gap UpCOEPCoeptis Therapeutics0.4396 of 5 stars$9.25-4.3%N/A+51.1%$31.13MN/A-1.592Short Interest ↑News CoverageOSTXOS Therapies1.7797 of 5 stars$1.43+2.1%$18.00+1,158.7%N/A$30.98MN/A0.00N/AALGSAligos Therapeutics3.5545 of 5 stars$5.05-15.1%$70.00+1,286.1%-75.0%$30.88M$3.95M-0.3890High Trading VolumeNRXPNRx Pharmaceuticals1.7987 of 5 stars$1.81+1.1%$28.25+1,460.8%-36.5%$30.62MN/A-0.852Short Interest ↑MRNSMarinus Pharmaceuticals2.1302 of 5 stars$0.55-0.2%$4.79+771.6%-60.2%$30.32M$30.99M-0.22110Analyst ForecastNews CoverageLTRNLantern Pharma1.9684 of 5 stars$2.81-6.0%$25.00+789.7%-36.0%$30.31MN/A-1.5820Gap Up Related Companies and Tools Related Companies Surrozen Competitors Estrella Immunopharma Competitors Kezar Life Sciences Competitors SCYNEXIS Competitors Coeptis Therapeutics Competitors OS Therapies Competitors Aligos Therapeutics Competitors NRx Pharmaceuticals Competitors Marinus Pharmaceuticals Competitors Lantern Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CHRO) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
